Abstract: In recent years, the incidence rate of type 2 diabetes (T2DM) and obesity in children and teenagers in China is increasing year by year. However, currently there are limited drugs approved domestically for the treatment of T2DM and obesity in children and teenagers, and the failure rate is high. In recent years, studies have shown that glucagon like peptide-1 receptor agonists (GLP-1RA) are effective and have good short-term safety in lowering blood sugar and weight loss in children and teenagers with T2DM and obese patients. However, children and teenagers in the growth and development stage have different reactions and tolerance levels to GLP-1RA compared to adults, and the incidence of gastrointestinal adverse reactions and hypoglycemia is significantly increased. Therefore, it is necessary to pay attention to the safety of their long-term use, and more systematic research and long-term follow-up evaluation should be further conducted.